MA34580B1 - Valsartan hautement cristallin - Google Patents

Valsartan hautement cristallin

Info

Publication number
MA34580B1
MA34580B1 MA35701A MA35701A MA34580B1 MA 34580 B1 MA34580 B1 MA 34580B1 MA 35701 A MA35701 A MA 35701A MA 35701 A MA35701 A MA 35701A MA 34580 B1 MA34580 B1 MA 34580B1
Authority
MA
Morocco
Prior art keywords
valsartan
highly crystalline
highly
preparation
pharmaceutical compositions
Prior art date
Application number
MA35701A
Other languages
English (en)
Inventor
Jens Burgbacher
Bjoern Thomas Hahn
Florian Andreas Rampf
Ricardo Schneeberger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34580B1 publication Critical patent/MA34580B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une forme de valsartan hautement cristalline, ses compositions pharmaceutiques et son procédé de préparation.
MA35701A 2010-08-03 2011-08-01 Valsartan hautement cristallin MA34580B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37028510P 2010-08-03 2010-08-03
PCT/EP2011/063254 WO2012016969A1 (fr) 2010-08-03 2011-08-01 Valsartan hautement cristallin

Publications (1)

Publication Number Publication Date
MA34580B1 true MA34580B1 (fr) 2013-10-02

Family

ID=44645072

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35701A MA34580B1 (fr) 2010-08-03 2011-08-01 Valsartan hautement cristallin

Country Status (18)

Country Link
US (1) US20130137737A1 (fr)
EP (1) EP2601180A1 (fr)
JP (1) JP2013532707A (fr)
KR (1) KR20130139863A (fr)
CN (1) CN103052630A (fr)
AR (1) AR082435A1 (fr)
AU (1) AU2011287616A1 (fr)
BR (1) BR112013002589A2 (fr)
CA (1) CA2806657A1 (fr)
CL (1) CL2013000335A1 (fr)
CO (1) CO6670580A2 (fr)
EC (1) ECSP13012459A (fr)
MA (1) MA34580B1 (fr)
MX (1) MX2013001251A (fr)
RU (1) RU2013109365A (fr)
SG (1) SG187007A1 (fr)
TW (1) TW201206428A (fr)
WO (1) WO2012016969A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739564A (zh) * 2012-02-20 2014-04-23 中国科学院上海药物研究所 缬沙坦的多晶型及其制备方法
CN103435567B (zh) * 2013-09-09 2015-08-26 山东新华制药股份有限公司 缬沙坦的精制方法
CN105801506A (zh) * 2014-12-30 2016-07-27 天津法莫西医药科技有限公司 缬沙坦新晶型及其制备方法
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法
CN105777660A (zh) * 2016-03-29 2016-07-20 潍坊盛瑜药业有限公司 缬沙坦晶型e的诱导结晶工艺及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
CN1137887C (zh) * 2000-04-07 2004-02-11 常州四药制药有限公司 一种合成缬沙坦的改进方法
HU229280B1 (en) 2000-07-19 2013-10-28 Novartis Ag Valsartan salts
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
WO2003089417A1 (fr) * 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Nouvelles formes cristallines de (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
US20040242661A1 (en) 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
CN101265239A (zh) * 2003-03-17 2008-09-17 特瓦制药工业有限公司 缬沙坦的多晶型
CZ298685B6 (cs) * 2003-05-15 2007-12-19 Zentiva, A.S. Zpusob výroby N-(1-oxopentyl)-N-[[2´-(1H-tetrazol-5-yl)[1,1´-bifenyl]-4-yl]methyl]-L-valinu (valsartanu)
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
CN101103006A (zh) 2005-01-11 2008-01-09 特瓦制药工业有限公司 无定形缬沙坦的制备方法
EP1896433A4 (fr) 2005-05-25 2010-06-02 Ipca Lab Ltd Nouvelles formes cristallines de (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
ITMI20051989A1 (it) * 2005-10-20 2007-04-21 Dipharma Spa Procedimerntyo per la preparazione di composti antagonisti di angiotensina ii
WO2007069271A2 (fr) * 2005-10-31 2007-06-21 Alembic Limited Procede de purification d'une (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
CN1844110B (zh) * 2005-12-09 2010-07-14 浙江天宇药业有限公司 高光学纯度的缬沙坦的合成方法
CN101270096B (zh) * 2007-03-22 2011-08-03 浙江华海药业股份有限公司 一种合成缬沙坦的方法
CN100522953C (zh) * 2007-04-03 2009-08-05 浙江天宇药业有限公司 一种缬沙坦的新合成方法
ES2316281B1 (es) * 2007-05-14 2010-02-09 Quimica Sintetica, S.A. Procedimiento para la preparacion de valsartan.
CN101362728B (zh) * 2008-08-22 2011-07-20 北京赛科药业有限责任公司 一种缬沙坦的合成方法
CN101768128B (zh) * 2009-01-05 2012-10-10 浙江华海药业股份有限公司 一种含10%以上异构体的缬沙坦的精制方法
CN101475540B (zh) * 2009-01-22 2011-05-11 江苏德峰药业有限公司 一种缬沙坦的制备方法
CN101735164A (zh) * 2009-12-22 2010-06-16 北京赛科药业有限责任公司 缬沙坦中杂质f的研究及控制方法

Also Published As

Publication number Publication date
RU2013109365A (ru) 2014-09-10
CA2806657A1 (fr) 2012-02-09
CL2013000335A1 (es) 2013-06-14
AR082435A1 (es) 2012-12-05
ECSP13012459A (es) 2013-03-28
JP2013532707A (ja) 2013-08-19
SG187007A1 (en) 2013-02-28
EP2601180A1 (fr) 2013-06-12
US20130137737A1 (en) 2013-05-30
WO2012016969A1 (fr) 2012-02-09
BR112013002589A2 (pt) 2019-09-24
AU2011287616A1 (en) 2013-02-28
TW201206428A (en) 2012-02-16
CN103052630A (zh) 2013-04-17
MX2013001251A (es) 2013-03-18
KR20130139863A (ko) 2013-12-23
CO6670580A2 (es) 2013-05-15

Similar Documents

Publication Publication Date Title
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MY158504A (en) Fatty acid niacin conjugates and their uses
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
UA105229C2 (uk) Фармацевтичний склад
MX2013001677A (es) Formulaciones estables de linaclotida.
TN2012000248A1 (en) Novel spiropiperidine compounds
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
GEP20166450B (en) Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
NZ601383A (en) Methods and compositions for improved nerve conduction velocity
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2010049449A3 (fr) Nouveaux sels de sunitinib
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
MA34580B1 (fr) Valsartan hautement cristallin
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
UA118562C2 (uk) Модулятори рецептора cxcr7
UA112764C2 (uk) Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок
WO2011050054A3 (fr) Composés coumarine en tant que modulateurs de récepteurs possédant une utilité thérapeutique
UA103996C2 (en) Ivabradine hydrobromide